Loading...
Loading...
Indian Pharmaceutical Exporter Β· #7 for Lansoprazole Β· $2.1M export value Β· DGFT Verified
Zydus Lifesciences Limited is the #7 Indian exporter of Lansoprazole with $2.1M in export value and 43 verified shipments. Zydus Lifesciences Limited holds a 0.9% market share in Lansoprazole exports across 3 countries. The company exports 81 pharmaceutical products worth $346.3M across 25 therapeutic categories.

| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $1.7M | 34 | 94.2% |
| FRANCE | $83.9K | 7 | 4.6% |
| TAIWAN | $20.7K | 2 | 1.1% |
Zydus Lifesciences Limited exports Lansoprazole to 3 countries. The largest destination is UNITED STATES accounting for 94.2% of Zydus Lifesciences Limited's Lansoprazole shipments, followed by FRANCE (4.6%) and TAIWAN (1.1%). These destinations reflect Zydus Lifesciences Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| EVERSANA LIFE SCIENCE SERVICES | UNITED STATES | $1.7M | 34 |
| CENTRE SPECIALITES PHARMACEUTIQUES | FRANCE | $42.3K | 4 |
| CENTRE SP?CIALIT?S PHARMACEUTIQUES | FRANCE | $41.6K | 3 |
| YI YOU BIOMEDICAL CO., LTD. | TAIWAN | $20.7K | 2 |
Zydus Lifesciences Limited supplies Lansoprazole to 4 buyers globally. The largest buyer is EVERSANA LIFE SCIENCE SERVICES (UNITED STATES), followed by CENTRE SPECIALITES PHARMACEUTIQUES (FRANCE) and CENTRE SP?CIALIT?S PHARMACEUTIQUES (FRANCE). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
India exported $71.7M worth of Lansoprazole through 4,867 shipments from 316 suppliers to 105 countries, serving 687 buyers globally. Zydus Lifesciences Limited contributes $2.1M to this total, accounting for 0.9% of India's Lansoprazole exports. Zydus Lifesciences Limited ships Lansoprazole to 3 countries through 4 buyers.
Zydus Lifesciences Limited's average Lansoprazole shipment value is $50.0K per consignment, based on 43 shipments totaling $2.1M. The largest destination is UNITED STATES (94.2% of Zydus Lifesciences Limited's Lansoprazole exports).
Zydus Lifesciences Limited ranks #7 among 316 Indian Lansoprazole exporters with a 0.9% market share. The top 3 exporters are MYLAN LABORATORIES LIMITED ($20.8M), CIPLA LIMITED ($11.3M), CAPLIN POINT LABORATORIES LIMITED ($6.4M). Zydus Lifesciences Limited processed 43 shipments to 3 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| LANSOPRAZOLE DR OD TAB 30 MG - 10 X 10 | $350.0K | 7 |
| LANSOPRAZOLE DR OD TAB 30 MG - 10 X 10TBS | $300.0K | 6 |
| LANSOPRAZOLE DR OD TAB 15 MG - 10 X 10TBS | $300.0K | 6 |
| LANSOPRAZOLE DR OD TAB 15 MG - 10 X 10DIST. NDC - 68382-771-77 MFG. NDC - 70771-1132-4 (AS PER INVOICE. & P.LIST)NOS | $150.0K | 3 |
| LANSOPRAZOLE DR OD TAB 30 MG - 10 X 10 (OTHER DETAILS AS PER INV & P.LIST) | $150.0K | 3 |
| LANSOPRAZOLE DR OD TAB 15 MG - 10 X 10 | $100.0K | 2 |
| PHARMACEUTICAL MEDICINE FOR HUMAN USE -LANSOPRAZOLE DR OD TAB 30 MG - 10 X 10 | $100.0K | 2 |
| LANSOPRAZOLE DR OD TABLETS 30MG [10X10 P | $50.0K | 1 |
What Zydus Lifesciences Limited must comply with to export Lansoprazole to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10β18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Exporters ranked immediately above and below #7 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 10 | MICRO LABS LIMITED | $3.7M | 87 | 16 | $42.7K |
| 1 | SANDOZ PRIVATE LIMITED | $3.5M | 69 | 2 | $50.0K |
| 7 | ZYDUS LIFESCIENCES LIMITED β | $2.1M | 43 | 3 | $50.0K |
| 12 | ALKEM LABORATORIES LIMITED | $2.0M | 40 |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 729 | 15.0% |
| DELHI AIR CARGO ACC (INDEL4) | 577 | 11.9% |
| SAHAR AIR CARGO ACC (INBOM4) | 416 | 8.5% |
| DELHI AIR | 364 | 7.5% |
| NHAVA SHEVA SEA (INNSA1) | 264 | 5.4% |
| JNPT/ NHAVA SHEVA SEA | 209 | 4.3% |
| Bombay Air | 140 | 2.9% |
| JNPT | 106 | 2.2% |
Zydus Lifesciences's export operations are influenced by various geopolitical factors. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing shipping costs and transit times for Indian exporters. This situation necessitates strategic logistics planning to mitigate potential delays and cost escalations.
Conversely, U.S.-China trade tensions have opened opportunities for Indian pharmaceutical companies like Zydus to capture a larger share of the U.S. market, as American importers seek alternative suppliers. Zydus's recent FDA approvals, including Niacin ER Tablets and Leuprolide Acetate injection, position the company to capitalize on this shift. (ainvest.com)
In the European Union, compliance with the Falsified Medicines Directive (FMD) is crucial for market access. Zydus's proactive measures to align with these regulations enhance its credibility and competitiveness in the EU market. However, the ongoing Israel-Iran conflict poses risks to Middle East trade routes, potentially affecting Zydus's operations in that region.
Maintaining stringent quality standards is paramount for Zydus Lifesciences. In October 2025, the company received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the U.S. FDA for its Baddi manufacturing facility, indicating compliance with regulatory standards. (bajajbroking.in) Similarly, the Ahmedabad SEZ-II facility received a clean USFDA report in November 2025, further affirming the company's commitment to quality. (bajajbroking.in)
These regulatory approvals are critical, as non-compliance can lead to import bans and reputational damage. Zydus's adherence to Good Manufacturing Practices (GMP) and proactive engagement with regulatory bodies underscore its dedication to maintaining high-quality standards across its operations.
Zydus Lifesciences Limited exports 81 products worth $346.3M. Beyond Lansoprazole, top products include Losartan, Carvedilol, Iron, Mesalamine, Omeprazole. View the complete Zydus Lifesciences Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Lansoprazole β including regulatory updates, trade policy changes, and competitive landscape analysis β will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records β the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Zydus Lifesciences Limited's Lansoprazole exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Zydus Lifesciences Limited
Full Company Profile β
81 products Β· $346.3M total trade Β· 25 categories
| PHARMA : LANSOPRAZOLE DR OD TABLETS 30MG | $50.0K | 1 |
| LANSOPRAZOLE DR OD TABLETS 30MG [2916 PACK X 10 X 10] | $50.0K | 1 |
Zydus Lifesciences Limited exports 18 distinct Lansoprazole formulations including tablets, capsules, syrups, and combination drugs. The top formulation is LANSOPRAZOLE DR OD TAB 30 MG - 10 X 10 with 7 shipments worth $350.0K.
| 2 |
| $50.0K |
| 13 | INVENTIA HEALTHCARE LIMITED | $1.9M | 55 | 2 | $33.9K |
Zydus Lifesciences Limited ranks #7 among 316 Indian Lansoprazole exporters. Average shipment value of $50.0K compared to the market average of $227.0K. The closest competitors by value are MICRO LABS LIMITED and SANDOZ PRIVATE LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 105+ countries, 687+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Zydus Lifesciences Limited.
Request DemoView Pricing βTrade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Lansoprazole. For current shipment-level data, contact TransData Nexus.